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Abstract: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders charac-
terized by peripheral blood cytopenias, blood cells dysplasia, and increased risk for progression to acute leukemia.
Physicians should be vigilant in diagnosing MDS and should be aware of the contemporary therapies that are always 
in progress. Most of the data on MDS epidemiology and management comes from developed countries. The inci-
dence and features of MDS in the Arab countries, among them Lebanon, are not known. We undertook a nationwide 
epidemiological registry study of all newly diagnosed MDS cases through 2010-2011. Patients were referred by 21 
hematologists/oncologists practicing in 17 hospitals and medical centers distributed across the entire country. 58 
patients (29 males and 29 females) with confirmed MDS were included. The calculated incidence rate of MDS was 
0.71 per 100,000 people. The median age at diagnosis was 73 years (range 16-86). The most common complaints 
on presentation were fatigue (70.7%), weakness (60.3%) and pallor (43.1%). Most patients were diagnosed as 
refractory anemia with excess blasts (RAEB; 36.2%) and refractory cytopenia with multilineage dysplasia (RCMD; 
32.8%). This paper constitutes the first epidemiological report on the incidence and specific subtypes of MDS in 
Lebanon. 
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Introduction
Myelodysplastic syndromes (MDS) are a het-
erogeneous group of clonal hematologic disor-
ders characterized by peripheral blood cytope-
nias, dysplasia of blood cells, clonal chromo- 
somal abnormalities, and increased risk of pro-
gression to acute myeloid leukemia [1, 2]. MDS 
generally arise de novo especially in older 
patients (primary MDS), or less frequently are 
secondary to prior chemotherapy or radiothera-
py (secondary or treatment-related MDS) [3]. 
Median age at disease onset is approximately 
70 years. Common risk factors for developing 
MDS include advanced age, male gender, smok-
ing, history of chemo- or radiotherapy, and 
exposure to agricultural chemicals [4-6]. 
Although MDS are common, the precise inci-
dence of the disease in developed countries 
MDS in Lebanon
87 Am J Blood Res 2015;5(2):86-90
has been difficult to estimate. In the United 
States, cancer registries such as the Sur- 
veillance, Epidemiology, and End Results 
(SEER) registry of the National Cancer Institute 
(NCI) have only started classifying MDS as neo-
plastic and capture data on newly diagnosed 
MDS cases since 2001 [7]. Numbers obtained 
from insurance claims data have been used to 
estimate the disease incidence. According to 
these sources, current estimates are between 
30,000 and 40,000 new MDS cases in the 
United States yearly [8, 9]. The incidence rate 
of MDS in Europe is estimated at 1.8-2.8 per 
100,000 people [10, 11]. 
Data on the incidence of MDS in the Arab coun-
tries is not known, and in Lebanon data is lack-
ing due to the absence of population-based 
hematologic malignancies registries. Conse- 
quently, the clinical and pathological features 
of MDS cases in Lebanon are not known. We 
undertook a nationwide initiative to prospec-
tively collect newly diagnosed MDS cases in 
Lebanon aiming at estimating the annual inci-
dence of this disease and better understand its 
clinical and pathological characteristics. 
Patients and methods
We conducted a prospective nationwide epide-
miological data registry on MDS in Lebanon. All 
adolescent and adult patients diagnosed with 
MDS during 2010-2011 were eligible for this 
registry. Institutional Review Board approval 
was obtained from all participating centers. 
Signed informed consents were required from 
enrolled patients. This nationwide collaboration 
was conducted through the study CRO (Clin- 
Serv International). Hematopathology revision 
of all cases was undertaken by one of our 
hematopathologists (H.F.).
Patients with a clinicopathological diagnosis of 
MDS were enrolled. Clinical and pathology data 
were collected in a data sheet by the principal 
investigator and co-investigators at the partici-
pating centers. The available pathology materi-
als from each patient were reviewed according 
to the 2008 World Health Organization (WHO) 
classification system of myeloid neoplasms 
[12]. 
Our initial search enrolled 80 patients with 
MDS. Patients not fulfilling the inclusion criteria 
and those without enough clinicopathological 
information to determine the MDS subtype 
were excluded from the analysis. The selection 
of patients for analysis was based on the algo-
rithm shown in Figure 1. The International 
Prognostic Scoring System (IPSS) and the 
revised IPSS (IPSS-R) were calculated as 
described previously [13, 14]. All data analysis 
was performed in SPSS software (Version 22, 
IBM, Armonk, NY, USA). 
Results
Our initial search enrolled 80 patients with 
MDS. However, only 58 patients with confirmed 
MDS were included in the final analysis. There 
were 29 (50%) males and 29 (50%) females. 
The median age at diagnosis was 73 years 
(range 16-86). These patients were referred by 
21 hematologists/oncologists practicing in 17 
hospitals and medical centers distributed 
across the 5 districts in Lebanon.
Figure 1. Algorithm describ-
ing excluded patients.
Table 1. Initial characteristics of patients
Characteristics Number (%)
Age (years)
    < 40 3 (5.2)
    40-49 3 (5.2)
    50-59 5 (8.6)
    60-69 6 (10.3)
    70-79 29 (50)
    ≥ 80 12 (20.7)
Gender
    Male 29 (50)
Family history of malignancy
    Yes 3 (5.2)
    No 46 (79.3)
    Unknown 9 (15.5)
History of radiation exposure
    Yes 2 (3.4)
    No 56 (96.6)
MDS in Lebanon
88 Am J Blood Res 2015;5(2):86-90
Sixteen patients (27.6%) had a history of ane-
mia and 3 (5.2%) had family history of malig-
nancy. The most common complaints on pre-
sentation were fatigue (70.7%), weakness 
(60.3%), pallor (43.1%), fever (12.1%), bruising 
(12.1%), bleeding (10.3%), and weight loss 
(10.3%). Table 1 summarizes the initial charac-
teristics of eligible patients. 
At baseline, 49 (84.5%) patients had abnormal-
ities on complete blood count (CBC). The medi-
an hemoglobin level for patients was 9.2 g/dL 
(range, 4.39-12.8 g/dL); most of the patients 
presented with hemoglobin levels below 10 g/
dL (Table 2). The median absolute neutrophil 
count (ANC) for patients was 2.33×109/L 
(range, 0.28×109-10.9×109/L). The median 
platelet count was 101×109/mm3. 
The median bone marrow blast count recorded 
at baseline was 2% (range, 0-19%). Eryth- 
rodysplasia was the most common observed 
dysplasia in 45 (77.6%) cases. In 14 (24.1%) 
patients there was a trilinear dysplasia. 
Examining the MDS subtypes, most patients 
were diagnosed as refractory anemia with 
Discussion
Here, we present the first nationwide prospec-
tive epidemiological study reporting the inci-
dence and features of MDS in Lebanon. We 
were able to confirm the diagnosis in 58 
patients with MDS who presented in 2010-
2011. These patients were managed in 17 hos-
pitals and medical centers distributed across 
the entire country; these hospitals represent 
over half of the hospitals in Lebanon.The popu-
lation of Lebanon was estimated to be 
4,100,000 people in 2011. This yields an inci-
dence rate of MDS of 0.71 per 100,000 people. 
This number is probably an underestimation of 
the true incidence of MDS in Lebanon if we 
account for missed cases and patients seen at 
hospitals other than the ones participating in 
this study. Taking that into account, MDS inci-
dence in Lebanon is comparable to other coun-
tries like Japan (1.6 cases per 100,000 for men 
and 0.8 cases for women in 2008) [15] and 
China (1.48 cases per 100,000 for men and 
1.54 cases for women) [16]. The incidence in 
Western countries appears to be higher rang-
ing between 2 and 4 cases per 100,000 [9, 17, 
18].
Table 2. Initial laboratory values on diagnosis
Parameters Number of cases Median Range
WBC 53 4600/µL 1300-18780
ANC 50 2331/µL 280-10906
    < 1000/µL 11 (22%)
    < 500/µL 2 (4%)
AMC 52 270/µL 7-2629
RBC 45 3.26×106/µL 1.94-4.43
Hgb 56 9.2 g/dL 4.39-12.8
    < 10 g/dL 34 (60.7%)
    < 8 g/dL 12 (21.4%)
MCV (fl) 48 93 74-114
Platelets 55 101×103/µL 12-422
    < 100×103/µL 26 (47.3%)
    < 50×103/µL 10 (18.2%)
    < 20×103/µL 3 (5.4%)
LDH (U/L) 37 183 30-382
Ferritin (µg/L) 32 187 6-2642
Marrow blasts 2% 0-19
    > 5% 17 (31.5%)
    > 10% 9 (16.7%)
    > 15% 5 (9.2%)
Abbreviations: WBC, white blood cell; ANC, absolute neutrophil count; AMC, 
absolute monocyte count; RBC, red blood cell; Hgb, hemoglobin; MCV, 
mean corpuscular volume; LDH, lactate dehydrogenase.
excess blasts (RAEB; 36.2%) and 
refractory cytopenia with multilin-
eage dysplasia (RCMD; 32.8%) 
(Table 3). Cytogenetic analysis 
showed a normal karyotype in 32/53 
(60.4%), monosomy 7 in 2/53 
(3.8%), complex karyotype in 5/53 
(9.4%), chromosome Y deletion in 
5/53 (9.4%), trisomy 8 in 3/53 
(5.7%), and other abnormalities in 
14/53 (26.4%).
When patients were charted accord-
ing to the calculated IPSS, 24.1% 
were low risk; 41.4% and 15.5% of 
patients were in the intermediate-1 
and -2 ranges, respectively; and only 
one patient (1.7%) was high risk. In 
10 patients the score could not be 
calculated due to missing informa-
tion. When the revised IPSS (IPSS- 
R) was calculated, 12.1% were very 
low risk, 34.5% were low risk, 22.7% 
were intermediate risk, 5.2% were 
high risk, and 8.6% were very high 
risk. IPSS-R could not be calculated 
in 11 patients due to missing infor-
mation (Table 4). 
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Characteristics of MDS patients have been 
shown to vary with ethnicity [19, 20]. Contrary 
to the general trend of male predominance in 
MDS, we did not see this gender difference in 
our study. This appears to be also the case in 
China [16]. The median age at diagnosis was 
73 years which is comparable to that in Europe 
and the United States [7, 19, 21].
We used the WHO 2008 classification criteria 
for myeloid malignancies. The most prevalent 
MDS subtype in our study was refractory ane-
mia with excess blasts (RAEB; 36.2%) followed 
by refractory cytopenia with multilineage dys-
plasia (RCMD; 32.8%). We noticed a relatively 
increased prevalence of RAEB among our 
MDS is significantly worse when the disease is 
more advanced.
The strength of our study is that we used a 
nationwide approach encompassing the major-
ity of hospitals in all districts of the country to 
identify newly diagnosed MDS patients. Most 
importantly, enrolled cases were reviewed by 
our hematopathologist to confirm MDS diagno-
sis and subtyping. 
Several limitations of our study should be 
addressed. Although we only enrolled cases 
with enough clinicopathological information to 
determine the MDS subtype, still some cases 
lacked relevant clinical and laboratory informa-
tion. We did not intend to assess MDS treat-
ment and outcome during this study. However, 
we believe that collecting this information is 
important for a thorough national MDS registry. 
Another weakness of this study was the lack of 
a panel of pathologists to be able to render 
more confirmatory findings.
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Table 3. MDS subtypes according to 2008 WHO classification
MDS subtype Number (%)
Refractory anemia (RA) 4 (6.9)
RA with ring sideroblasts (RARS) 7 (12.1)
Refractory cytopenia with multilineage dysplasia (RCMD) 19 (32.8)
Refractory anemia with excess blasts-1 (RAEB-1) 9 (15.5)
Refractory anemia with excess blasts-2 (RAEB-2) 12 (20.7)
MDS associated with isolated del (5q) 1 (1.7)
Myelodysplastic syndrome-unclassified (MDS-U) 6 (10.3)




    Normal 32 (55.2)
    Abnormal 21 (36.2)
    Uninformative 2 (3.4)
    Missing 3 (5.2)
IPSS score
    Low 14 (24.1)
    Intermediate-1 24 (41.4)
    Intermediate-2 9 (15.5)
    High 1 (1.7)
    Missing 10 (17.2)
IPSS-R score
    Very low 7 (12.1)
    Low 20 (34.5)
    Intermediate 12 (20.7)
    High 3 (5.2)
    Very high 5 (8.6)
    Missing 11 (19)
Abbreviations: IPSS, International Prognostic Scoring 
System; IPSS-R, revised International Prognostic Scoring 
System.
patients as compared to pub-
lished literature [11]. This finding 
may perhaps be attributed to the 
late presentation of patients in 
the course of the disease. This 
represents an opportunity to edu-
cate patients about the manifes-
tations of the disease in order to 
seek medical attention earlier in 
the course of the disease. This is 
important as the prognosis of 
MDS in Lebanon
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